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REVIEW
Tiotropium bromide
David A Lipson
Pulmonary, Allergy, and Critical Care 
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Abstract: Therapy with bronchodilators forms the pharmacologic foundation of the 
treatment of patients with COPD. Bronchodilators can signiﬁ  cantly lessen dyspnea, increase 
airﬂ  ow, improve quality of life, and enhance exercise performance. While bronchodilators 
decrease airway resistance and lessen dynamic hyperinﬂ  ation in patients with COPD, they 
have not been shown to alter the rate of decline in FEV1 over time, or improve patient 
survival. Fairly recently, a long-acting, once-daily anticholinergic medication, tiotropium 
bromide, has been developed which may improve symptom management in COPD patients. 
This paper reviews anticholinergic pharmacologic therapy for patients with COPD focus-
ing on tiotropium bromide, and discusses treatment strategies based on disease stage. It 
is important to recognize that while bronchodilators improve symptoms, a multimodality 
treatment approach including respiratory and rehabilitative therapy, nutrition services, 
psychosocial counseling, and surgical care, is often necessary for the best possible care of 
patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an enormous health threat that 
currently ranks as the fourth leading cause of morbidity and mortality in the US 
(National Heart, Lung, and Blood Institute 1998), and is the only major disease with 
increasing mortality (Benson and Marano 1998; Centers for Disease Control and 
Prevention 1999). In the year 2000, COPD accounted for over 1.5 million visits to 
emergency departments in the US (Mannino et al. 2002). The prevalence of COPD 
is also exploding internationally. By the year 2020, the World Bank and the World 
Health Organization project that COPD will rank ﬁ  fth as a cause of worldwide 
disability (Murray and Lopez 1997a, 1997b, 1997c). Given the increasing patient 
population, there has been a great push to develop medications that will appreciably 
affect the care of patients with this devastating and costly disease (Croxton et al 
2003).
Anticholinergic medications are a class of drugs that have long been used to 
improve symptomatology of patients with COPD (Gross 1988; Dollery 1991; Bauer 
1992). A new inhaled anticholinergic medication, tiotropium bromide (Boehringer 
Ingelheim, Ingelheim, Germany), is now being used in this patient population. This 
medication appears to be more effective in treating patients with COPD compared with 
older anticholinergics. This review will discuss the pharmacology of anticholinergic 
bronchodilators focusing on tiotropium bromide, and discuss treatment strategies 
based on disease stage.
Methods
A Cochrane Database and MEDLINE search from 1966 to October 2005, and a 
search of the PubMed database using the terms COPD, emphysema, tiotropium, 
anticholinergic, and autonomic nervous system was performed. Bibliographies 
of identiﬁ  ed articles were then reviewed for further references. Non-English, 
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and non-human studies were excluded. Bibliographies of 
review articles were examined and original research was 
then systematically evaluated.
Pharmacology of the autonomic 
nervous system
The autonomic nervous system through cholinergic nerve 
ﬁ  bers is responsible for mediating mucus secretion and 
bronchial smooth muscle tone in the lung. Branches of the 
vagus nerve innervate muscarinic cholinergic (M) receptors 
in parasympathetic ganglia in the lung using acetylcholine 
as the primary neurotransmitter. No less than 5 muscarinic 
cholinergic receptor subtypes (M1–M5) have been identiﬁ  ed 
in the lung. M1 and M3 mediate bronchoconstriction and mucus 
production. M2 is a presynaptic postganglionic autoreceptor 
in small airways that inhibits the M1 and M3 receptors via 
negative feedback mechanisms (Figure 1). Stimulation of the 
M2 receptor inhibits cholinergic action in the lung, so agonism 
of this receptor leads to inhibition of bronchoconstriction. At 
this time, the M4 and M5 receptors have poorly understood 
function in the lung (Mak et al 1993; Barnes 1993a, 1993b; 
Barnes et al. 1997; ZuWallack 2004). 
Older anticholinergic medications, such as ipratropium 
(Figure 2), block the M1, M2, and M3 receptors. Speciﬁ  -
cally, these medications decrease the bronchoconstrictive 
action of the M1 and M3 receptors, but also block the inhibi-
tory action of the M2 receptor. Ipratropium then dissociates 
fairly quickly from these receptors. Thus, ipratropium is a 
weak bronchodilator because of its relatively short half-life 
compared with newer anticholinergics, and because of its 
inhibitory action on the M2 receptor. A new anticholinergic 
called tiotropium bromide (Figure 3) has been developed 
which also antagonizes M1, M2, and M3 receptors. However, 
tiotropium quickly dissociates from the M2 receptor, and 
thus its net effect is that of a selective M1 and M3 antagonist. 
Tiotropium, therefore, blocks the bronchoconstrictive action 
of the M1 and M3 muscarinic receptors while allowing M2 
inhibition of bronchoconstriction to continue. Slow dissocia-
tion of tiotropium from the M1 and M3 receptors accounts 
for its long half-life.
Anticholinergic medications
Ipratropium
Anticholinergic medications (Table 1) are some of the 
most common medications used in the treatment of COPD 
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Figure 1 Pulmonary muscarinic cholinergic receptors. M1 and M3 receptors medi-
ate bronchoconstriction and mucus production in the lung. M2 receptors inhibit M1 
and M3 receptors via negative feedback. Ipratropium inhibits all three muscarinic 
receptors. Tiotropium quickly dissociates from the M2 receptor but continues to 
antagonize the M1 and M3 receptor. Thus, tiotropium blocks bronchoconstriction 
and allows inhibition of bronchoconstriction to continue. The slow dissociation of 
tiotropium from the M1 and M3 receptors accounts for its long half-life.
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Figure 3 Tiotropium bromide. Note the similarity to ipratropium (Figure 2) and 
the presence of the quaternary nitrogen group, which is responsible for its efﬁ  cacy.International Journal of COPD 2006:1(2) 109
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and have been used safely for decades (Anthonisen et al 
1994). They are available for delivery by both metered 
dose inhaler and nebulizer. Their duration of action varies 
between 4 and 36 hours. Most anticholinergics, such as 
ipratropium, are quaternary ammonium derivatives that 
have difﬁ  culty crossing the blood–brain barrier and are 
poorly absorbed in the body (Ferguson 2000). The quater-
nary ammonium structure likely enhances their efﬁ  cacy 
and minimizes the side-effects that beleaguer β-agonists. 
These medications have been shown to diminish the sense 
of dyspnea, and mucus hypersecretion via their inhibition 
of the cholinergic system (Ghafouri et al 1984). Anticholin-
ergics have also been shown to improve oxyhemoglobin 
saturation with sleep (Martin et al 1999; McNicholas et al 
2004), and provide similar, or greater, bronchodilation 
compared with β2-agonists (Karpel 1991; COMBIVENT 
Inhalation Aerosol Study Group 1994; Rennard et al 1996). 
Data suggest that in some patients who have COPD, iprat-
ropium may be effective when β2-agonists are not effective 
(Braun and Levy 1991). Anticholinergics have a reasonable 
safety proﬁ  le, and are not prone to receptor downregulation 
or tachyphylaxis (Rennard et al 1996). However, these 
medications may be associated with an increased number 
of adverse cardiovascular events in patients with COPD 
(Anthonisen et al 2002).
Combining ipratropium with long-acting β2-agonists 
may also have additive beneﬁ  ts for patients. Van Noord et al 
(2000) studied salmeterol compared with salmeterol plus 
ipratropium. The study found that both salmeterol alone or 
in combination with ipratropium improved bronchodilation 
compared with placebo, but the combination of the medica-
tions appeared to elicit a greater bronchodilator response 
and improvement in FEV1 than salmeterol alone. Dorinsky 
et al (1999) found that the combination of ipratropium 
and albuterol was superior to either medication alone in 
identifying patients with reversibility on spirometric testing 
of pulmonary function.
Tiotropium
Tiotropium, with its extremely long duration of action, 
avoids one of the main limitations of ﬁ  rst-generation anti-
cholinergic medications – the necessity of frequent dosing. 
Casaburi et al (2002) showed that once-daily tiotropium, 
compared with placebo, improved bronchodilation, 
dyspnea scores, health status scores, and decreased COPD 
exacerbations and hospitalizations. The primary adverse 
side-effect observed in the study was dry mouth. In a fairly 
short 12-week study in patients with COPD, tiotropium 
was shown to provide a higher post-dose FEV1, and higher 
peak and FVC, compared with salmeterol (Briggs et al 
2005). In a 6-month study of tiotropium compared with 
salmeterol, tiotropium produced a greater degree of bron-
chodilation, reduction in dyspnea scores, and improvement 
in health-related quality of life (Donohue 2002). In a longer 
1-year study, Vincken et al (2002) demonstrated diminished 
salbutamol use and improvement in peak expiratory ﬂ  ow 
rates. Compared with ipratropium, tiotropium appeared 
to reduce the number of exacerbations, increase the 
time to a ﬁ  rst exacerbation, and increase the time to ﬁ  rst 
hospitalization in patients with COPD. Quality of life 
scores were also improved. More recently, a randomized, 
placebo-controlled study of tiotropium in mostly male 
veterans with COPD showed a decrease in exacerbation 
rate compared with placebo. While the effect was small, 
it was statistically signiﬁ  cant (Niewoehner et al 2005). At 
this time, it is not known whether this effect would also 
be seen in women.
Anticholinergics and exercise 
tolerance
Numerous studies have demonstrated improvements in 
exercise tolerance in patients with COPD with the use 
of anticholinergic medications (Spence et al 1993). Hay 
et al (1992) studied the use of oxitropium in patients with 
COPD. The study showed signiﬁ  cant improvements in 
breathlessness and walking distance, and an increased 
FEV1 with its use. Improvements in walking distances and 
symptoms were unrelated to changes in either FEV1 or 
FVC, which may suggest that routine reversibility testing 
is not a good predictor of symptomatic beneﬁ  t in patients 
with COPD.
Table 1 Anticholinergics used in the management of COPD
Drug  Metered  Nebulizer  Time to   Duration 
 dose  (mg)  peak  (hr)
 inhaler  (μg)      effect (hr) 
ipratropium 40–80  0.25–0.5  1–2  4–6
oxitropium 200  –  1–2  6–7
albuterol–ipratropiuma  90/18 – 1–2 6–8
tiotropium 18  –  2–3  24–36
Adapted from Dollery (1991), Bauer (1992), Gross (1988), Lipson (2004).
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Tsukino et al (1998) investigated the combined effect of 
theophylline with ipratropium. The study found that both 
ipratropium and theophylline improved exercise tolerance 
but combination therapy with the two medications produced 
greater improvements in pulmonary function and exercise 
capacity than either drug alone. In this study the average 
serum theophylline levels were around 18.3 μg/mL, which 
increases the risk of adverse side-effects.
Casaburi et al (2005) showed that the combination of 
tiotropium in combination with pulmonary rehabilitation 
improved treadmill endurance and reduced dyspnea scores 
compared with rehabilitation alone. These effects seemed 
to be sustained for at least 3 months after the rehabilitation 
course was completed. Maltais et al (2005) demonstrated 
that tiotropium improved symptom-limited exercise toler-
ance compared with placebo in COPD patients up to 8 hours 
following dosing.
Tiotropium also appears to reduce lung hyperinﬂ  ation at 
rest and during exertion (Celli et al 2003; Maltais et al 2005). 
This may be an important effect as dynamic hyperinﬂ  ation 
likely contributes to the sense of dyspnea that often limits 
exercise in COPD patients (O’Donnell et al 1998; Taube 
et al 2000). Following 4 weeks of therapy, tiotropium clearly 
improves lung volumes compared with placebo (Figure 4) 
(Celli et al 2003).
Recently, combination therapies using tiotropium have 
been shown to be beneﬁ  cial in the treatment of patients 
with COPD. van Noord et al (2005) have demonstrated 
that tiotropium produces a greater improvement in daytime 
FEV1 than formoterol. Interestingly, night-time change 
in FEV1 was not different between the two medications. 
However, combination therapy with the two medications 
(with daily dosing) improved FEV1 to the greatest extent. 
While combination therapy appears to be a trend in caring 
for patients with more advanced disease, it is important to 
recognize that individual and combination pharmacologic 
medications are expensive, add signiﬁ  cantly to the cost 
of healthcare, and have not been found to alter the over-
all decline in lung function seen in patients with COPD. 
Additional studies will be necessary to determine the best 
combination(s) of bronchodilators in the treatment of 
patients with COPD.
The staging of COPD
Various respiratory societies, including the American 
Thoracic Society (ATS) and the European Respiratory 
Society (ERS), have developed staging systems to help 
identify patients at risk for COPD and to aid in standardi-
zation of therapies and clinical trials. The ATS guidelines 
for staging COPD are shown in Table 2 (ATS 1995). “Stage 
0” disease describes a smoker with normal spirometry 
who has symptoms of chronic mucus production or cough. 
“Stage I” or “Mild COPD” describes the patient with 
Table 2 Stages of COPD
Stage Findings
0: At Risk  Normal spirometry
  Chronic cough, sputum production, dyspnea
I: Mild COPD  FEV1/FVC < 70%
 FEV1
a > 80% predicted
  May have chronic cough, sputum production, 
dyspnea
IIA: Moderate COPD  FEV1/FVC < 70%
 50% < FEV1< 80% predicted
  May have chronic cough, sputum production, 
dyspnea
IIB: Moderate COPD  FEV1/FVC < 70%
 30% < FEV1 < 50% predicted
  May have chronic cough, sputum production, 
dyspnea
III: Severe COPD  FEV1/FVC < 70%
 FEV1 < 30% predicted or FEV1 < 50% predicted 
and either respiratory failureb or cor pulmonale
Adapted from ATS (1995).
aall FEV1 values refer to post bronchodilator measurements.
bPaO2 < 60 mmHg.
Figure 4 Tiotropium improves lung volumes compared with placebo. Repro-
duced from Celli B, ZuWallack R, Wang S, et al. 2003. Improvement in resting 
inspiratory capacity and hyperinﬂ  ation with tiotropium in COPD patients with 
increased static lung volumes. Chest, 124:1743–8. Copyright © 2003, with permis-
sion from CHEST.
Abbreviations: FRC, functional residual capacity; IC, inspiratory capacity; SVC, 
slow vital capacity.
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objective spirometric evidence of airﬂ  ow obstruction. Their 
FEV1/FVC ratio is < 70%, and their post-bronchodilator 
FEV1 is   80% of predicted. They may or may not have 
symptoms of airﬂ  ow obstruction, chronic bronchitis, or 
dyspnea. “Stage II” or “Moderate COPD” is character-
ized by typical symptoms, airﬂ  ow obstruction with the 
FEV1/FVC ratio < 70%, and the FEV1 between 30% and 
80% of predicted. It is considered “IIA” disease if the 
FEV1 is   50% of predicted, and “IIB” disease if the FEV1 
falls between 30% and 50% of predicted. “Stage III” or 
“Severe COPD” is characterized by appropriate symptoma-
tology, a FEV1/FVC ratio < 70%, and a FEV1 < 30% of 
predicted. Evidence of respiratory failure or cor pulmonale, 
with a FEV1 < 50% of predicted, is also consistent with 
“Severe” disease.
Treatment according to disease 
stage
Spirometry should be used to help identify and stage patients 
with COPD as their treatment is often predicated upon disease 
stage (Figure 5) (Lipson 2004). However, following stable 
patients with multiple repeat spirometric tests may not be 
useful (Wilt et al 2005). “At risk” patients must refrain from 
cigarette smoking, and should obtain annual inﬂ  uenza vac-
cination and should be vaccinated with the pneumococcal 
vaccine every 5 years. Bronchodilator therapy on an “as 
Figure 5 Treatment of COPD by stage. Reproduced from Lipson DA. 2004. Redeﬁ  ning treatment in COPD: new directions in bronchodilator therapy. Treat Respir Med, 
3:89–95. Erratum in Treat Respir Med, 3:181. Copyright © 2004, with permission from Adis International Ltd.
Abbreviations: LVRS, lung volume reduction surgery. 
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needed” basis with short-acting bronchodilators may be used 
for managing mild COPD patients (Vathenen et al 1988).
A combination of short- and long-acting bronchodila-
tors is often used to treat moderate emphysema. Inhaled 
anticholinergic medications and combinations of short- and 
long-acting β2-agonists are standard treatments. Inhaled 
corticosteroids may be useful for patients with more 
severe disease, or those patients with a partially reversible, 
bronchospastic component to airﬂ  ow obstruction. These 
medications may also be useful in patients who have 
repeated exacerbations (Burge et al 2000; The Lung Health 
Study Research Group 2000; Sin and Tu 2001; Hattotuwa 
et al 2002). Medications combining an inhaled steroid and 
a long-acting β-agonist, such as ﬂ  uticasone and salmeterol, 
may also be useful in this patient population (Mahler 
et al 2002).
Pulmonary rehabilitation is an important addition to 
pharmacologic therapy in patients with COPD because 
severe dyspnea leads to a sedentary lifestyle, subsequent 
deconditioning, and muscle weakness (ACCP/AACVPR 
Pulmonary Rehabilitation Guidelines Panel 1997). Pulmo-
nary rehabilitation increases strength, quality of life, sense 
of well-being, and exercise tolerance. It is also useful in 
breaking the vicious cycle of progressive debilitation in 
patients with advanced lung disease (Fishman 1994; Celli 
1997; ATS 1999).
All patients with moderate COPD should be evaluated 
for the need for supplemental oxygen. Patients who exhibit 
oxyhemoglobin desaturation at rest, or with exertion, should 
be prescribed supplemental oxygen to maintain oxyhemo-
globin saturations greater than 90%. Long-term oxygen 
therapy, in COPD patients who require it, has been shown 
to improve survival, exercise tolerance, and quality of life 
(Nocturnal Oxygen Therapy Trial Group 1980; Medical 
Research Council Working Party 1981; Tarp and Celli 1995). 
A patient requires supplemental oxygen if they demonstrate 
an oxyhemoglobin saturation < 88% or a PaO2 < 55 mmHg. 
Additionally, an oxyhemoglobin saturation < 89% or a 
PaO2 < 60 mmHg also qualiﬁ  es a patient for supplemental 
oxygen if there is evidence of cor pulmonale, a hematocrit 
> 56%, dependent edema, or other signs suggestive of heart 
failure.
The treatment of severe COPD is equivalent to that of 
moderate disease, except patients in this stage should also 
be evaluated for potential surgical treatments such as lung 
volume reduction surgery or lung transplantation (Cooper 
et al 1996; Sciurba et al 1996; Arcasoy and Kotloff 1999; 
Criner et al 1999; Geddes et al 2000; Flaherty et al 2001; 
Kotloff et al 2001; National Emphysema Treatment Trial 
Research Group 2001, 2003).
Conclusions
Anticholinergic medications are safe and useful adjuncts in 
the care of patients with COPD. While they have not been 
shown to alter the rate of decline in the FEV1, or alter survival, 
they improve exercise tolerance, dynamic hyperinﬂ  ation, 
and breathlessness. These medications improve quality of 
life measures and reduce the risk of exacerbation (Barr et al 
2005). Newer anticholinergics, such as tiotropium, have the 
added advantage of once-daily dosing and more speciﬁ  c 
cholinergic receptor targets.
Clearly, the best treatment of COPD remains smoking 
cessation and abstinence from smoking. Evaluation and care 
of the patient with COPD must include respiratory and reha-
bilitative therapy, nutrition services, psychosocial counseling, 
and evaluation for the need for long-term oxygen therapy. 
Physicians, and persons charged with caring for patients 
with COPD, await the development of novel therapies that 
will further improve survival, and the quality of the lives of 
patients with lung disease.
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